Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:2 Issue:7 Number:161 ISSN#:2563-5476
RCT
ACE Report #740
Ace Report Cover Arthroplasty

No significant difference between Dabigatran etexilate and enoxaparin in VTE occurrence


How to Cite

OrthoEvidence. No significant difference between Dabigatran etexilate and enoxaparin in VTE occurrence . ACE Report. 2013;2(7):161. Available from: https://myorthoevidene.com/AceReport/Report/740

Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial

Lancet. 2007 Sep 15;370(9591):949-56

Contributing Authors: BI Eriksson OE Dahl N Rosencher AA Kurth CN van Dijk SP Frostick MH Prins R Hettiarachchi S Hantel J Schnee HR Büller

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

3494 patients undergoing total hip replacement were randomized to either receive 220mg of Dabigatran etexilate, 150mg of Dabigatran etexilate, or enoxaparin. The results following the treatment period (33 days) indicate that there were no significant differences between all three groups in terms of reducing the risk of major venous thromboembolism and all-cause mortality. In addition the safety ou...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE

Please Login or Join to leave comments.